Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions

Life Sciences

Volumn 86, Issue 11-12, 2010, Pages 402-409

  Nawa, Ayaka ^a   Fujita Hamabe, Wakako ^a   Tokuyama, Shogo ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Diabetes; Ileum; Inducible nitric oxide synthase; P glycoprotein

Indexed keywords

AMINOGUANIDINE; GLYCOPROTEIN P; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; ILEUM MUCOSA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; URINE VOLUME;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CYTOPLASM; DIABETES MELLITUS, EXPERIMENTAL; DRINKING; EATING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; INSULIN; INTESTINAL MUCOSA; INTESTINES; MALE; MEMBRANES; MICE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; P-GLYCOPROTEIN; URODYNAMICS;

MUS;

EID: 77949537263     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.01.009     Document Type: Article

References (47)

1. Adibi S.A. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. American Journal of Physiology Gastrointestinal and Liver Physiology 2003, 285(5):G779-G788.
2. Al-Shawi M.K., Omote H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. Journal of Bioenergetics and Biomembranes 2005, 37(6):489-496.
3. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 1999, 39:361-398.
4. Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of co-morbid depression in adults with diabetes. Diabetes Care 2001, 24(6):1069-1078.
5. Andrew P.J., Mayer B. Enzymatic function of nitric oxide synthases. Cardiovascular Research 1999, 43(3):521-531.
6. Ballent M., Lifschitz A., Virkel G., Sallovitz J., Lanusse C. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34(3):457-463.
7. Bauer B., Hartz A.M., Miller D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular Pharmacology 2007, 71(3):667-675.
8. Cao X., Yu L.X., Barbaciru C., Landowski C.P., Shin H.C., Gibbs S., Miller H.A., Amidon G.L., Sun D. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Molecular Pharmaceutics 2005, 2(4):329-340.
9. Cornwell M.M. Molecular biology of P-glycoprotein. Cancer Treatment and Research 1991, 57:37-56.
10. Doluisio J.T., Billups N.F., Dittert L.W., Sugita E.T., Swintosky J.V. Drug absorption I: an in situ rat gut technique yielding realistic absorption rates. Journal of Pharmaceutical Sciences 1969, 58(10):1196-1200.
11. Dong Z.G., Hong J.Y., Ma Q.A., Li D.C., Bullock J., Gonzalez F.J., Park S.S., Gelboin H.V., Yang C.S. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Archives of Biochemistry and Biophysics 1988, 263(1):29-35.
12. Dyer J., Wood IS Palejwala A., Ellis A., Shirazi-Beechey S.P. Expression of monosaccharide transporters in intestine of diabetic humans. American Journal of Physiology. Gastrointestinal and Liver Physiology 2002, 282(2):G241-G248.
13. Ghosh D.K., Crane B.R., Ghosh S., Wolan D., Gachhui R., Crooks C., Presta A., Tainer J.A., Getzoff E.D., Stuehr D.J. Inducible nitric oxide synthase: role of the N-terminal beta-hairpin hook and pterin-binding segment in dimerization and tetrahydrobiopterin interaction. EMBO Journal 1999, 18(22):6260-6270.
14. Goodyer I.M., Herbert J., Tamplin A., Altham P.M. First-episode major depression in adolescents. Affective, cognitive and endocrine characteristics of risk status and predictors of onset. The British Journal of Psychiatry: The Journal of Mental Science 2000, 176:142-149.
15. Heemskerk S., van Koppen A., van den Broek L., Poelen G.J., Wouterse A.C., Dijkman H.B., Russel F.G., Masereeuw R. Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Archiv: European Journal of Physiology 2007, 454(2):321-334.
16. Iida A., Tomita M., Hayashi M. Regional difference in P-glycoprotein function in rat intestine. Drug Metabolism and Pharmacokinetics 2005, 20(2):100-106.
17. Jackson M.W., Gordon T.P., Waterman S.A. Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes. Gastroenterology 2004, 126(3):819-828.
18. Kageyama M., Fukushima K., Togawa T., Fujimoto K., Taki M., Nishimura A., Ito Y., Sugioka N., Shibata N., Takada K. Relationship between excretion clearance of Rhodamine123 and P-glycoprotein (P-gp) expression induced by representative P-gp inducers. Biological & Pharmaceutical Bulletin 2006, 29(4):779-784.
19. Kim E., Sohn S., Lee M., Jung J., Kineman R.D., Park S. Differential responses of the growth hormone axis in two rat models of streptozotocin-induced insulinopenic diabetes. Journal of Endocrinology 2006, 188(2):263-270.
20. Kim H.Y., Kang K.S., Yamabe N., Nagai R., Yokozawa T. Protective effect of heat-processed American ginseng against diabetic renal damage in rats. Journal of Agricultural and Food Chemistry 2007, 55(21):8491-8497.
21. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47(6):859-866.
22. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51(2):216-226.
23. Liu X.D., Pan G.Y., Xie L., Hou Y.Y., Lan W., Su Q., Liu G.Q. Cyclosporine A enhanced protein of nimodipine against brain damage induced by hypoxia-ischemia in mice and rats. Acta Pharmacologica Sinica 2002, 23(3):225-229.
24. Liu H., Yang H., Wang D., Liu Y., Liu X., Li Y., Xie L., Wang G. Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via an insulin receptor-mediated PKC/NF-kappaB pathway but not a PI3K/Akt pathway. European Journal of Pharmacology 2009, 602(2-3):277-282.
25. Maeng H.J., Kim M.H., Jin H.E., Shin S.M., Tsuruo T., Kim S.G., Kim D.D., Shim C.K., Chung S.J. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2007, 35(11):1996-2005.
26. Marchetti S., Mazzanti R., Beijnen J.H., Schellens J.H. Concise review: clinical relevance of drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007, 12(6):927-941.
27. Marchetti S., de Vries N.A., Buckle T., Bolijn M.J., van Eijndhoven M.A., Beijnen J.H., Mazzanti R., van Tellingen O., Schellens J.H. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics 2008, 7(8):2280-2287.
28. Marletta M.A. Nitric oxide synthase structure and mechanism. Journal of Biological Chemistry 1993, 268(17):12231-12234.
29. Martin M.T., Azpiroz F., Malagelada J.R. Ileal brake failure in streptozotocin-induced diabetic rat. Scandinavian Journal of Gastroenterology 2004, 39(5):423-427.
30. Miyazawa T., Kubo E., Takamura Y., Akagi Y. Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract. Experimental Eye Research 2007, 84(2):246-253.
31. Mizuno N., Niwa T. Drug transporter studies in drug discovery and development. Nippon Yakurigaku Zasshi 2005, 125(4):200-206. (Japanese).
32. Narimatsu N., Saito M., Kazuyama E., Hisadome Y., Kinoshita Y., Satoh I., Okada S., Suzuki H., Yamada M., Satoh K. N-hexacosanol prevents diabetes-induced rat ileal dysfunction without qualitative alteration of the muscarinic receptor system. Biomedical Research 2007, 28(5):267-273.
33. Powell L.A., Warpeha K.M., Xu W., Walker B., Trimble E.R. High glucose decrease intracellular glutathione concentrations and upregulates inducible nitric oxide synthase gene expression in intestinal epithelial cells. Journal of Molecular Endocrinology 2004, 33(3):797-803.
34. Ramana K.V., Friedrich B., Tammali R., West M.B., Bhatnagar A., Srivastava S.K. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 2005, 54(3):818-829.
35. Ranjan M., Nayak S., Rao B.S. Immunochemical detection of glycated beta- and gamma-crystallins in lends and their circulating autoantibodies (IgG) in streptozotocin induced diabetic rat. Molecular Vision 2006, 12:1077-1085.
36. Rittenhouse P.A., Marchand J.E., Chen J., Kream R.M., Leeman S.E. Streptozotocin-induced diabetes is associated with altered expression of peptide-encoding mRNA in rat sensory neurons. Peptides 1996, 17(6):1017-1022.
37. Saha R.N., Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxidants Redox Signaling 2006, 8(5-6):929-947.
38. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2000, 12(1):3-12.
39. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research/Academia Scientiarum Bohemoslovaca 2001, 50(6):537-546.
40. Tada Y., Wada M., Kuroiwa K., Kinugawa N., Harada T., Nagayama J., Nakagawa M., Naito S., Kuwano M. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2000, 6(12):4618-4627.
41. Taylor B.S., Alarcon L.H., Billiar T.R. Inducible nitric oxide synthase in the liver: regulation and function. Biochemistry 1998, 63(7):766-781.
42. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003, 419(1):31-40.
43. Tramonti G., Xie P., Wallner EI Danesh F.R., Kanwar Y.S. Expression and functional characteristic of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. American Journal of Physiology. Renal Physiology 2006, 291(5):972-980.
44. Tsuji A. Can we predict pharmacokinetic profiles of drugs in human from data of experimental animals?. Drug Delivery System 2007, 22(1):43-47. (Japanese with English abstract).
45. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. Journal of Biological Chemistry 1992, 267(34):24248-24252.
46. Valentovic M.A., Alejandro N., Betts Carpenter A., Brown P.I., Ramos K. Streptozotocin (STZ) diabetes enhances benzo(alpha)pyrene induced renal injury in Sprague Dawley rats. Toxicology Letters 2006, 3(164):214-220.
47. Van Waarde W.M., Verkade H.J., Wolters H., Havinga R., Baller J., Bloks V., Müller M., Sauer P.J., Kuipers F. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 2002, 122(7):1842-1852.